Co-delivery of a STING agonist and indoleamine 2,3-dioxygenase 1 blockade activates type I dendritic cells in cancer
{{output}}
The stimulator of interferon genes (STING) has emerged as a promising target for cancer immunotherapy. However, STING agonists alone have demonstrated limited clinical success. Indoleamine 2,3-dioxygenase 1 (IDO1) has been implicated as a key resistance mechan... ...
